IcanoMAB Announces a Novel IL-18 Signaling Blocker (anti-IL-1R7) Ready for Development for the Treatment of the Cytokine-Release-Syndrome in Late-stag

Search jobs
19-May-2021
IcanoMAB Announces a Novel IL-18 Signaling Blocker (anti-IL-1R7) Ready for Development for the Treatment of the Cytokine-Release-Syndrome in Late-stage Covid-19
IcanoMAB Announces a Novel IL-18 Signaling Blocker (anti-IL-1R7) Ready for Development for the Treatment of the Cytokine-Release-Syndrome in Late-stage Covid-19
Positive regulatory advice received for development plan to provide POC in late-stage COVID-19 patients
Additional opportunities in indications related to Cytokine-Release Syndrome, e.g., ARDS, MAS and acute inflammatory diseases
Pre-clinical proof-of-concept recently published with Charles Dinarello, University of Colorado, Denver
Partner discussions in preparation to exploit full therapeutic potential
POLLING, Germany, May 17, 2021 / B3C newswire / -- IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision antibodies for the treatment of cancer, immune-system related diseases and COVID-19, today announced that it has received positive regulatory advice for the clinical development path of its anti-IL-1R7 antibody in late-stage COVID-19. In addition, IcanoMAB has published the pre-clinical proof-of-concept for the anti-IL-1R7 antibody that blocks the signal transduction of the interleukin-18 (IL-18) receptor.

Related Keywords

Colorado ,United States ,Germany ,Netherlands ,University Of Colorado Denver ,Nijmegen ,Gelderland ,Denver ,Stephan Fischer ,Ulrich Pessara ,Charles Dinarello ,Daniel Parera ,Boehringer Mannheim ,Dinarello Lab ,Institute Of Clinical Medicine Aarhus University Hospital ,Department Of Infectious Disease ,Novartis ,Radboud University Medical Center ,University Of Colorado ,Department Of Medicine ,Cytokine Release Syndrome ,Pre Clinical Proof Of Concept ,Colorado Denver ,Infectious Disease ,Clinical Medicine Aarhus University Hospital ,Acute Respiratory Distress Syndrome ,Macrophage Activation Syndrome ,Xantos Biomedicine ,கொலராடோ ,ஒன்றுபட்டது மாநிலங்களில் ,ஜெர்மனி ,நெதர்லாந்து ,பல்கலைக்கழகம் ஆஃப் கொலராடோ டென்வர் ,டென்வர் ,போஹெரிங்கர் மேன்ஹெய்ம் ,துறை ஆஃப் தொற்று நோய் ,நோவர்த்திச் ,பல்கலைக்கழகம் ஆஃப் கொலராடோ ,துறை ஆஃப் மருந்து ,கொலராடோ டென்வர் ,தொற்று நோய் ,எடுப்போசை சுவாச துன்பம் நோய்க்குறி ,